ArticleBMC women's health2026
Immune checkpoint profiling in unexplained female infertility: a prospective study.
Article in BMC women's health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo explore the serum levels of soluble PD-1 (sPD-1), soluble OX40 ligand (sOX40L), soluble CD40 ligand (sCD40L), soluble CD25 (sCD25) and soluble B7H3 (sB7H3) during the early to mid-secretory phase (days 15–19 of the menstrual cycle) in women with unexplained infertility (UI) and to evaluate their feasibility as non-invasive biomarkers.
methodThis retrospective study included 50 patients with UI (defined as infertility without identifiable causes after comprehensive evaluation) and 45 healthy women as controls, recruited from the First Affiliated Hospital of Soochow University between January 2022 and January 2023. On days 15–19 of the menstrual cycle (early to mid-secretory phase), cubital venous blood was collected from fasting participants by needle in both groups. Serum levels of the soluble molecules were measured using an enzyme-linked immunosorbent assay. Associations with UI were analyzed using multivariate logistic regression and receiver operating characteristic (ROC) curve analysis.
resultsSerum levels of sPD-1, sCD40L, sOX40L and sCD25 were significantly elevated in patients with UI compared with the controls, whereas sB7H3 was significantly decreased. In multivariate analysis, sOX40L and sCD25 were identified as factors independently associated with UI. The combination of sOX40L and sCD25 was associated with an area under the ROC curve of 0.826, a sensitivity of 78.0%, and a specificity of 80.0% in this cohort.
conclusionElevated serum levels of sOX40L and sCD25 are significantly associated with UI. The combination of these markers showed an association with UI in our analysis, suggesting their potential for further investigation as non-invasive biomarkers. These findings support the hypothesis that immune dysregulation may contribute to UI and highlight the need for further validation in larger cohorts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.